Clene Inc.
CLNN
NASDAQ·Healthcare·Biotechnology·Mkt cap $49.2M
$3.85
▼ -3.63%
P/E
-1.08
Mkt Cap
$49.2M
52-Wk Range
$3.72–$13.50
52-Week Range
$3.72 - $13.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 41.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary clean-surfaced nanotechnology platform with broad therapeutic applications
- First-mover advantage in CSN-based therapeutics for neurodegeneration
- Diversified pipeline reducing single-asset risk and expanding addressable markets
- Experienced management team with pharmaceutical development expertise
Bear Case
1 risk
- Average volatility.
Growth
Strong growth ahead
CNM-Au8 Phase 2/3 ALS trial progression toward potential FDA approval
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Falling
-27.8% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CLNN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 14, 2026
Reported EPS of -$1.08 vs -$0.37 consensus (-193.5% surprise). Revenue of $90.0K vs $61.0K expected (+47.5%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-193.5%
Revenue trend · last 8Q
—
—
+11%
-70%
-83%
-15%
-81%
+233%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$87.0K
$91.0K
$81.0K
$27.0K
$15.0K
$77.0K
$15.0K
$90.0K
Margins · last 8Q
Gross
60.0%
Profit
-14915.6%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: D. Boral Capital · May 4, 2026
vs Industry
How CLNN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related